GENECODE is a private Estonian-American-Finnish-Dutch R&D company, developing novel disease modifying drugs. Our overall ambition is to develop neuroprotective and potentially neurorestorative treatment which is –as yet- unavailable. With respect to anti-viral strategies, GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. Our scientific partners are all internationally well known leading scientists.
November 29th & 30th, 2022
December 7th & 8th, 2022